Featured News
April 15, 2025
Alkermes’ Statement on the Passing of Iain Brown, Chief Financial Officer
April 01, 2025
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Our Commitment to Responsibility
Corporate responsibility is inherent in our mission as an organization that actively works to support people living with complex and difficult-to-treat psychiatric and neurological disorders and to help break down barriers that prevent people from accessing care. As we do this important work, we strive to manage our business in a manner that promotes transparent governance and strong ethics; maintains extensive stakeholder engagement; and helps us grow our organization strategically, sustainably and responsibly. Our most recent Corporate Responsibility Report expounds on these efforts
Our Stories
Each endeavor at Alkermes starts with collaboration and our shared commitment to make a difference for patients and our communities. These stories – which highlight our people, science and innovation, and leadership perspectives – showcase just a subset of what makes us proud to be part of Alkermes. Visit our full gallery of stories by clicking on the link below.
Patient-Inspired Drug Development
We highlight the importance of engaging with the community to inform drug development in this new video.
World Sleep Day 2025: Spotlight on Idiopathic Hypersomnia
Julie Himes reflects on the experiences of people living with idiopathic hypersomnia for World Sleep Day.
Caregiver Spotlight: Monica Gow
Hear from Monica about lessons learned and the impact of her work as an advocate.
Media Resources
Company Description
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.
Follow us on our social channels
